Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Prestige Consumer Healthcare Inc. PBH

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.1B
▼ 4.3% YoY
$190.3M
▼ 11.3% YoY
$246.4M
▲ 1.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes brand name, over-the-counter health and personal care products to mass merchandisers, drug and drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America and in Australia and certain other international markets. It conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare. Walmart accounted for approximately 20% of its gross revenues during fiscal 2026. Its major brands accounted for approximately 83.5% of its total revenues for fiscal 2026. It was formed as a Delaware corporation in 1996. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc.

Written from the business description in Prestige Consumer Healthcare Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 May 2026. Every sentence was checked against that document before publication.

Growth

USD 1.1B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.1 · Net income 0.2
0.5B1.0B
2009201220152018202120242025
Compound annual growth
−1.2%
+2.9%
+3.0%
+8.1%
+2.9%
+6.7%
+13.3%
+3.8%
+7.6%
+13.6%
+52.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.9% a year over the five years to FY2025 — but profit grew faster: net income at +2.9%, earnings per share at +3.8%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

17 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 28.4% · Net 17.5%
10%20%30%-2%-4%-6%
200920172025
ROE
FY2025 · ROE 10.2%
10%20%30%-2%-4%
200920172025
Three returns, three denominators.

Each USD of equity produced 10 cents of profit this year.

Cash & shareholders

USD 152.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 246.4
100M200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 152.0
100M200M
20122014201620182020202220242025

USD 152.0M in buybacks — 80% of the year's profit went back to shareholders.

Total assetsUSD 3.5B
EquityUSD 1.9B
CashUSD 63.9M
Gross debtUSD 994.0M
Net debtUSD 930.1M
Current ratio3.57×

Net debt stands at 49% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
PBH, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.11.11.11.11.10.91.01.01.00.90.80.70.60.60.40.30.3
Operating income $B0.30.30.3−0.00.30.30.30.10.20.20.30.20.20.20.10.10.1
EBITDA $B0.30.40.40.00.40.30.30.10.20.20.30.20.20.20.10.10.1
Income tax $B0.10.10.1−0.00.10.00.0−0.0−0.20.00.10.00.00.00.00.00.0
Net income $B0.20.20.2−0.10.20.20.1−0.00.30.10.10.10.10.10.00.00.0
Free cash flow $B0.20.20.20.20.30.20.20.20.20.10.20.20.10.10.10.10.1
EPS, diluted $3.914.294.17−1.654.043.252.78−0.696.341.301.881.491.391.270.730.580.64
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %——————————0000———
ROE %10.212.313.5−5.414.013.012.6−3.133.98.914.613.113.914.99.78.59.8

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Eight checks were skipped: cost of revenue is not tagged before 2015. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated innot stated in the filings
Fiscal year endsMarch 31
Data on record since2009

Share this section

Download image